失智症藥物市場按藥物類別、適應症、給藥途徑、分銷管道和地區分類

2025 年全球失智症藥物市場規模估計為 261.4 億美元，預計 2032 年將達到 414.5 億美元，2025 年至 2032 年的複合年成長率為 6.8%。

市場佔有率。

失智症藥物市場的成長是由全球患有阿茲海默症和其他失智症的人數不斷增加所推動的。失智症是一種由影響大腦的疾病（例如阿茲海默症或中風）引起的綜合症。失智症的特徵是思考、記憶和推理等認知功能逐漸喪失。隨著人們對失智症診斷和治療方法認知的提高，越來越多的人尋求醫療協助來治療失智症症症狀。一些製藥公司正在投入大量開發有效藥物，以減緩或阻止失智症的進展。

市場動態

失智症治療市場的成長主要受到全球人口快速老化的推動，這增加了神經退化性疾病的風險。新興市場醫療支出的增加以及生物製藥公司密集的研發力度進一步促進了市場擴張。然而，藥物開發的高成本仍然是一個巨大的挑戰，特別是由於許多候選分子在後期臨床試驗中失敗，以及這些疾病的複雜性。最近核准的緩解疾病藥物旨在影響疾病的發病機製而不是簡單地緩解症狀，這對製造商來說是一個巨大的機會。政府對失智症研究的支持和資助不斷增加，鼓勵市場參與企業創新和開發新的治療方法。由於人口變化導致失智症盛行率持續上升，對有效治療方法的需求預計將成長，市場預計將取得重大進展。

研究的主要特點

本報告對全球失智症治療藥物市場進行了詳細分析，並以 2024 年為基準年，給出了預測期（2025-2032 年）的市場規模和年複合成長率（CAGR%）。

它還強調了各個領域的潛在商機，並說明了該市場的引人注目的投資提案矩陣。

它還提供了對市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景以及主要企業採用的競爭策略的重要見解。

全球失智症藥物市場的主要企業根據公司亮點、產品系列、關鍵成就和策略等參數進行分析。

主要企業包括 Biogen、Eisai Co., Ltd.、Novartis AG、Cipla、H. Lundbeck A/S、Otsuka Pharmaceutical Co., Ltd.、Sun Pharmaceutical Industries Ltd.、Viatris Inc.、Mapi-Pharma Ltd.、AbbVie, Inc.、DACHICHI SANKYO COA., LI-Pharma

本報告的見解將使負責人和企業經營團隊能夠就未來產品發布、新興趨勢、市場擴張和行銷策略做出明智的決策。

全球失智症藥物市場報告針對該行業的各個相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。

相關人員可以透過全球失智症藥物市場分析中使用的各種策略矩陣更輕鬆地做出決策。

目錄

第1章 調查目的與前提條件

• 研究目標
• 先決條件
• 簡稱

第2章 市場展望

• 報告描述
  • 市場定義和範圍
• 執行摘要

第3章市場動態、法規與趨勢分析

• 市場動態
• 影響分析
• 監管情景
• 產品發布/核准
• PEST分析
• 波特分析
• 併購情景
• 流行病學
• 管道分析

第 4失智症。

• 介紹
• MAO 抑制劑
• 膽鹼酯酶抑制劑
• 麩胺酸抑制劑
• 其他

第 5 章。

• 介紹
• 阿茲海默症失智症
• 路易氏體失智症
• 帕金森氏症失智症
• 其他

第 6失智症。

• 介紹
• 口服
• 靜脈
• 其他

第 7失智症。

• 介紹
• 醫院藥房
• 零售藥局
• 網路藥局

第 8 章。

• 介紹
• 北美洲
• 拉丁美洲
• 歐洲
• 亞太地區
• 中東
• 非洲

第9章 競爭格局

• Biogen
• Eisai Co., Ltd.
• Novartis AG
• Cipla
• Lundbeck A/S
• Otsuka Pharmaceutical Co., Ltd.
• Sun Pharmaceutical Industries Ltd.
• Viatris Inc.
• Mapi-Pharma Ltd.
• AbbVie, Inc.
• DAIICHI SANKYO COMPANY, LIMITED.
• Hoffmann-La Roche Ltd

第 10 章分析師建議

• 興衰
• 一致的機會地圖

第 11 章 參考文獻與調查方法

• 參考
• 調查方法
• 關於出版商

Global Dementia Drugs Market is estimated to be valued at USD 26.14 Bn in 2025 and is expected to reach USD 41.45 Bn by 2032, growing at a compound annual growth rate (CAGR) of 6.8% from 2025 to 2032.

Figure. Dementia Drugs Market Share (%), By Region 2025

Dementia drugs market growth is driven by rising cases of Alzheimer's and other forms of dementia worldwide. Dementia is a syndrome caused due to disorders that affect the brain, such as Alzheimer's disease or strokes. It is characterized by a gradual loss of cognitive functions like thinking, remembering and reasoning. Increasing awareness about diagnosis and availability of treatment options drive more people to seek medical help for dementia symptoms. Several pharmaceutical companies are investing heavily in research and development of effective drugs to slow down or stop the progression of dementia.

Market Dynamics

Dementia drugs market growth is primarily driven by rapidly aging global population, which increases the risk of neurodegenerative conditions. Rising healthcare expenditures in developing nations and intensive R&D efforts by biopharmaceutical firms further contribute to market expansion. However, high drug development costs, particularly due to the failure of many candidate molecules in late-stage trials and the complexity of these diseases, pose significant challenges. The recent approval of disease-modifying drugs that aim to impact disease etiology rather than merely alleviating symptoms presents substantial opportunities for manufacturers. Increased government support and funding for dementia research are encouraging market participants to innovate and develop new therapies. As the prevalence of dementia continues to rise, driven by demographic changes, the demand for effective treatments is expected to grow, positioning the market for significant advancements.

Key features of the study

This report provides in-depth analysis of the global dementia drugs market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global dementia drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Biogen, Eisai Co., Ltd., Novartis AG, Cipla, H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd., Sun Pharmaceutical Industries Ltd., Viatris Inc., Mapi-Pharma Ltd., AbbVie, Inc., DAIICHI SANKYO COMPANY, LIMITED., and F. Hoffmann-La Roche Ltd

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

Global dementia drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global dementia drugs market

Market Segmentation

• By Drug Class Insights (Revenue, USD Bn, 2019 - 2032)
  • MAO Inhibitors
  • Cholinesterase Inhibitors
  • Glutamate Inhibitor
  • Others
• By Indication Insights (Revenue, USD Bn, 2019 - 2032)
  • Alzheimer's Disease Dementia
  • Lewy Body Dementia
  • Parkinson Disease Dementia
  • Others
• By Route of Administration Insights (Revenue, USD Bn, 2019 - 2032)
  • Oral
  • Intravenous
  • Others
• By Distribution Channel Insights (Revenue, USD Bn, 2019 - 2032)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Regional Insights (Revenue, USD Bn, 2019 - 2032)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
  • Biogen
  • Eisai Co., Ltd.
  • Novartis AG
  • Cipla
  • Lundbeck A/S
  • Otsuka Pharmaceutical Co., Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Mapi-Pharma Ltd.
  • AbbVie, Inc.
  • DAIICHI SANKYO COMPANY, LIMITED.
  • Hoffmann-La Roche Ltd

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Dementia Drugs Market, By Drug Class
  • Dementia Drugs Market, By Indication
  • Dementia Drugs Market, By Route of Administration
  • Dementia Drugs Market, By Distribution Channel
  • Dementia Drugs Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario
• Epidemiology
• Pipeline Analysis

4. Dementia Drugs Market, By Drug Class, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• MAO Inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Cholinesterase Inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Glutamate Inhibitor
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Dementia Drugs Market, By Indication, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Alzheimer's Disease Dementia
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Lewy Body Dementia
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Parkinson Disease Dementia
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Dementia Drugs Market, By Route of Administration, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Intravenous
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Dementia Drugs Market, By Distribution Channel, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Dementia Drugs Market, By Region, 2020 - 2032, (USD Bn)

• Introduction
  • Market Share (%) Analysis, 2025,2028 & 2032, (USD Bn)
  • Market Y-o-Y Growth Analysis (%), 2021 - 2032, (USD Bn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Indication, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Indication, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Indication, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Indication, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Indication, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Indication, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Country/Region, 2020 - 2032, (USD Bn)
    • South Africa
    • North Africa
    • Central Africa

9. Competitive Landscape

• Biogen
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Eisai Co., Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Novartis AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Cipla
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Lundbeck A/S
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Otsuka Pharmaceutical Co., Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Sun Pharmaceutical Industries Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Viatris Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Mapi-Pharma Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• AbbVie, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• DAIICHI SANKYO COMPANY, LIMITED.
• Hoffmann-La Roche Ltd

10. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. References and Research Methodology

• References
• Research Methodology
• About us